McKesson stock: UBS raises target to USD 1,200 for McKesson stock

Published on 10/21/2026 at 17:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UBS set a USD 1,200 target on October 16, 2026. McKesson stock costs EUR 902.00 on October 21, 2026, up 1.39 percent versus Frankfurt close.

Analyst targets rise

UBS raised its McKesson target to USD 1,200 on October 16, 2026.
Fiscal 2027 first-quarter revenue reached USD 105.38 billion, up 7.70 percent year over year.
McKesson stock costs EUR 902.00 at Lang & Schwarz on October 21, 2026 at 5:30 p.m. CEST, 1.39 percent above the Frankfurt close of October 19, 2026.
McKesson is scheduled to release second-quarter fiscal 2027 results on November 4, 2026.

Mitarbeiter sortieren unbeschriftete Pakete in einem großen Pharma-Logistiklager mit Regalen — Fotorealistisches Bild zeigt McKesson Corporation ISIN US58155Q1031 als Pharmagroßhändler in modernem Distributionslager mit vielen Mitarbeitern, Illustration mit AI erstellt.

McKesson raised its analyst ceiling when UBS lifted the price target from USD 1,080 to USD 1,200 on October 16, 2026, while maintaining a Buy rating, according to MarketScreener. The target stood 18.61 percent above McKesson's USD 1,011.74 intraday price on the NYSE at 11:30 a.m. EDT on October 21, 2026. At Lang & Schwarz, the stock was trading at EUR 902.00 on October 21, 2026 at 5:30 p.m. CEST, up 1.39 percent versus the Frankfurt close of October 19, 2026 at EUR 889.60.

Two targets point higher

Mizuho also raised its target from USD 905.00 to USD 1,020.00 and kept a Neutral rating in a note issued on October 20, 2026, MarketBeat reported. The revised target was 0.82 percent above the NYSE price cited above, leaving a narrower gap than UBS's forecast.

Revenue reached USD 105.38 billion

McKesson's fiscal 2027 first-quarter revenue was USD 105.38 billion, up 7.70 percent from the prior-year quarter, while adjusted earnings guidance for fiscal 2027 stood at USD 44.20 to USD 45.00 per share, according to MarketBeat. The revenue comparison gives the analyst targets an operating backdrop, but the business remains a low-margin distributor: MarketBeat reported a 1.12 percent net margin for the quarter.

McKesson and its peers

McKesson carried a USD 117.96 billion market capitalization and a 27.09 price-to-earnings ratio on October 21, 2026. Cardinal Health traded at USD 257.06, down 0.19 percent from its prior close, with a USD 59.53 billion market capitalization and a 35.56 price-to-earnings ratio. Cencora traded at USD 339.03, down 1.24 percent, with a USD 64.70 billion market capitalization and a 25.19 price-to-earnings ratio.

November 4 sets the next date

McKesson is scheduled to release second-quarter fiscal 2027 earnings on November 4, 2026, according to MarketScreener. That report will provide the next scheduled test of the USD 44.20 to USD 45.00 fiscal-year adjusted earnings outlook.

Stock holds a higher valuation

The latest analyst targets place McKesson above the current NYSE quotation, while the peer comparison gives a mixed valuation picture. The stock's 1.39 percent euro gain versus the Frankfurt close keeps the immediate market signal positive for investors tracking the German quotation.

The further course of trading is shown by the continuously updated real-time quote of McKesson stock.